AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework - PubMed
3 days ago
- #Artificial Intelligence
- #Personalized Medicine
- #Type 2 Diabetes
- Type 2 diabetes (T2D) is a growing global health issue requiring innovative treatments.
- Semaglutide (Ozempic) is effective in lowering blood glucose, aiding weight loss, and reducing cardiovascular risks.
- Artificial intelligence (AI) enhances diabetes care by analyzing data from wearables, EHRs, and imaging for personalized treatment.
- This systematic review examines AI-driven methods to optimize Ozempic-based T2D therapy.
- 18 peer-reviewed articles identified four key themes: patient stratification, AI-enhanced imaging, risk assessment, and personalized dosing.
- AI-based approaches outperformed standard fixed-dose regimens in metrics like HbA1c reduction and weight loss.
- A proposed framework includes continuous data collection, AI processing, clinical decision support, and real-time feedback.
- Challenges include the need for large-scale trials, longer follow-ups, explainable AI, and regulatory validation.
- AI has potential to transform semaglutide therapy but requires further research for clinical implementation.